Gregory Baird, MD
General Practice · South Jordan, UTNPI 1902148133
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,912 of the $33,856 with a category attached, or 97.2%. Shire North American Group Inc accounts for 72.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $24,615 and has fallen 99.9% since, to $21 in 2025. Among general practice clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $769.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$24K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Acadia Pharmaceuticals Inc$657
- AbbVie$116
- Avanir Pharmaceuticals, Inc.$90
- Neurocrine Biosciences, Inc.$43
- plus $38 from 2 others
What the payments were for
- Consulting fees$32,91297%
- Food & beverage$9143%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 12 | $24,484 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $8,428 |
| Acadia Pharmaceuticals Inc | 15 | $657 |
| AbbVie | 2 | $116 |
| Avanir Pharmaceuticals, Inc. | 7 | $90 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Vapotherm Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,856 in reported general payments places this provider in the 95th percentile of 1,070 general practice providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 360 | $151,631 |
| TrulicityDulaglutide | 79 | $82,798 |
| JardianceEmpagliflozin | 170 | $79,203 |
| NuedextaDextromethorphan Hbr/Quinidine | 42 | $42,914 |
| FarxigaDapagliflozin Propanediol | 48 | $22,108 |
| TradjentaLinagliptin | 53 | $21,973 |
| MyrbetriqMirabegron | 43 | $17,125 |
| Duloxetine Hcl | 358 | $12,789 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $10,241 |
| XareltoRivaroxaban | 28 | $10,116 |
| Atorvastatin Calcium | 761 | $9,934 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,465 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $7,246 |
| Quetiapine Fumarate | 202 | $7,193 |
| LinzessLinaclotide | 12 | $6,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $90 | $42,91442 claims |
| AbbVieLinzess | $116 | $6,91812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 general practice providers in Utah.
Other general practice in South Jordan
- Ryan LewisSouth Jordan$735K
- Walter MedenSouth Jordan$12K
- James AndersonRoy$44.1M
- Mark LudlowWest Jordan$592K
- Eric SwensenWest Jordan$109K
- Brigham StokerSalt Lake City$82K
- Kelly OlsenSt George$65K
- Jared FlittonRoy$58K
- Jaimee MorganMidvale$51K
- Jeremy ThompsonRiverton$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.